An estimated 5.8 million Americans aged 65 and older were living with Alzheimer’s dementia in 2020. 80% of this population was aged 75 or older. This number is expected to increase to 13.5 million by 2050. Among people of age 70, 61% of those with Alzheimer’s dementia are expected to die before the age of 80 compared with 30% of people without Alzheimer’s. The rising prevalence of Alzheimer’s disease has increased the demand for the treatment, which in turn is expected to boost the market growth.
the global Alzheimer’s drugs market was pegged at ~US$ 4.5 billion in 2020. The market is expected to witness a CAGR of ~7.2% from 2021 to 2031.
Alzheimer’s drug development is considered to have the highest failure rates of all drug research, at 99.6% compared to 81% for cancer, according to Scientific American. The drug development process includes high capital investments, therefore, failures in drug research may prove to be huge loss for companies, thereby discouraging the companies to invest and participate in the clinical trials. In January 2018, Pfizer, announced to end its R&D on new drugs for Alzheimer’s and Parkinson’s diseases and reallocate the funding to areas where the company has strong scientific leadership. Pfizer is among the first companies to research Alzheimer’s. Such instances are expected to slow down the growth of the market.
To access the Sample PDF of this research study, please request here: https://growthplusreports.com/inquiry/request-sample/alzheimer%E2%80%99s-drugs-market/7614
Key players:
Daiichi Sankyo Company, Ltd, H. Lundbeck A/S, Novartis AG, Lupin Pharmaceuticals, Inc., Actiza Pharmaceutical Private Limited, Amneal Pharmaceuticals LLC., AC Immune, F. Hoffmann-La Roche Ltd, Janssen Global Services, and LLC, AbbVie Inc., among others.
Segmentation By Drug Type:
• NMDA Receptor Antagonists
• Cholinesterase Inhibitors
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Regional Analysis-
• The Asia-Pacific market is anticipated to grow at a higher CAGR during the forecast period.
• Major factors contributing to the growth of Alzheimer’s Drugs market in this region include the rising incidence of chronic infectious diseases, rising awareness regarding growing applications of Alzheimer’s Drugs, and increasing research activities in the field of Alzheimer’s Drugs.
• The emergence of local players and new product launches has also played a critical role in boosting the Alzheimer’s Drugs market in this region.
Browse the full report now: https://growthplusreports.com/report/alzheimer%E2%80%99s-drugs-market/7614
Key Questions Answered in the Report Include:
(1) This report gives all the information about the industry analysis, revenue, and overview, of this market.
(2) What will be the rate of increase in market size and growth rate by the end of the forecast period?
(3) What are the major global Alzheimer’s Drugs Market trends influencing the development of the market?
(4) What are the vital results of SWOT analysis of the major players operating in the Alzheimer’s Drugs Market?
(5) What are the potential growth opportunities and threats faced by Major competitors in the market?
About Us:
Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association). Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success. We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.